Table: Sawai Pharmaceutical -2019/20 group results (IFRS)

SAWAI group

14/05/2020 07:00

May 14 (Reuters)- 
              Sawai Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   Year ended      Year ended       Year to        NEXT  
                Mar 31, 2020    Mar 31, 2019   Mar 31, 2021      YEAR    
                   LATEST         YEAR-AGO        COMPANY      COMPANY   
                   RESULTS         RESULT        FORECAST    H1 FORECAST 
  Sales            182.54          184.34         200.20        96.00    
                 (-1.0 pct)      (+9.7 pct)     (+9.7 pct)    (+6.1 pct) 
  Operating         26.79           25.80          26.85        13.35    
                 (+3.9 pct)      (+16.2 pct)    (+0.2 pct)   (-12.5 pct) 
  Pretax            26.50           25.67          26.55        13.25    
                 (+3.2 pct)      (+26.7 pct)    (+0.2 pct)   (-12.6 pct) 
  Net               19.28           19.38          20.05         9.95    
                 (-0.5 pct)      (+38.2 pct)    (+4.0 pct)    (-9.3 pct) 
  EPS Basic      440.37 yen      442.62 yen     457.94 yen    227.26 yen 
  EPS Diluted    440.00 yen      442.32 yen                              
  Ann Div        130.00 yen      135.00 yen     130.00 yen               
  -Q2 Div         65.00 yen       65.00 yen      65.00 yen               
  -Q4 Div         65.00 yen       70.00 yen      65.00 yen               
 
  NOTE - Sawai Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4555.T